{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T17:05:05Z","timestamp":1788109505309,"version":"build-2803163510"},"reference-count":32,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Pediatr"],"published-print":{"date-parts":[[2020,9,1]]},"DOI":"10.1001\/jamapediatrics.2020.1990","type":"journal-article","created":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T16:03:11Z","timestamp":1595260991000},"page":"843","source":"Crossref","is-referenced-by-count":44,"title":["Incidence of Meningococcal Disease Before and After Implementation of Quadrivalent Meningococcal Conjugate Vaccine in the United States"],"prefix":"10.1001","volume":"174","author":[{"given":"Sarah","family":"Mbaeyi","sequence":"first","affiliation":[{"name":"Meningitis and Vaccine Preventable Diseases Branch, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Pondo","sequence":"additional","affiliation":[{"name":"Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Blain","sequence":"additional","affiliation":[{"name":"Meningitis and Vaccine Preventable Diseases Branch, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Yankey","sequence":"additional","affiliation":[{"name":"Assessment Branch, Immunization Services Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caelin","family":"Potts","sequence":"additional","affiliation":[{"name":"Meningitis and Vaccine Preventable Diseases Branch, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Cohn","sequence":"additional","affiliation":[{"name":"National Center for Immunization and Respiratory Diseases Office of the Director, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Hariri","sequence":"additional","affiliation":[{"name":"Meningitis and Vaccine Preventable Diseases Branch, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nong","family":"Shang","sequence":"additional","affiliation":[{"name":"Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica R.","family":"MacNeil","sequence":"additional","affiliation":[{"name":"National Center for Immunization and Respiratory Diseases Office of the Director, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"poi200034r1","doi-asserted-by":"publisher","first-page":"B3","DOI":"10.1016\/j.vaccine.2011.12.062","article-title":"Meningococcal disease: clinical presentation and sequelae.","volume":"30","author":"Pace","year":"2012","journal-title":"Vaccine"},{"issue":"8","key":"poi200034r2","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1093\/cid\/cix993","article-title":"Current epidemiology and trends in meningococcal disease\u2014United States, 1996-2015.","volume":"66","author":"MacNeil","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"12","key":"poi200034r3","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S1473-3099(10)70251-6","article-title":"Meningococcal carriage by age: a systematic review and meta-analysis.","volume":"10","author":"Christensen","year":"2010","journal-title":"Lancet Infect Dis"},{"issue":"RR-2","key":"poi200034r4","first-page":"1","article-title":"Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"62","author":"Cohn","year":"2013","journal-title":"MMWR Recomm Rep"},{"issue":"2","key":"poi200034r5","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-2193","article-title":"Effectiveness and duration of protection of one dose of a meningococcal conjugate vaccine.","volume":"139","author":"Cohn","year":"2017","journal-title":"Pediatrics"},{"issue":"33","key":"poi200034r6","doi-asserted-by":"publisher","first-page":"909","DOI":"10.15585\/mmwr.mm6733a1","article-title":"National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years\u2014United States, 2017.","volume":"67","author":"Walker","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"poi200034r10","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1086\/648977","article-title":"Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease.","volume":"50","author":"Cohn","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"41","key":"poi200034r12","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.15585\/mmwr.mm6441a3","article-title":"Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices, 2015.","volume":"64","author":"MacNeil","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"16","key":"poi200034r13","first-page":"352","article-title":"Benefits from immunization during the Vaccines for Children program era\u2014United States, 1994-2013.","volume":"63","author":"Whitney","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"6","key":"poi200034r14","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/j.jpeds.2014.02.025","article-title":"Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescents.","volume":"164","author":"Baxter","year":"2014","journal-title":"J Pediatr"},{"issue":"11","key":"poi200034r15","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1097\/INF.0000000000000438","article-title":"Antibody persistence after primary and booster doses of a quadrivalent meningococcal conjugate vaccine in adolescents.","volume":"33","author":"Baxter","year":"2014","journal-title":"Pediatr Infect Dis J"},{"issue":"11","key":"poi200034r16","doi-asserted-by":"publisher","first-page":"881","DOI":"10.4161\/hv.6.11.12849","article-title":"Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo\u00ae) or Menactra\u00ae among healthy adolescents.","volume":"6","author":"Gill","year":"2010","journal-title":"Hum Vaccin"},{"issue":"4","key":"poi200034r17","doi-asserted-by":"publisher","first-page":"e170","DOI":"10.1097\/INF.0b013e318279ac38","article-title":"Antibody persistence and response to a booster dose of a quadrivalent conjugate vaccine for meningococcal disease in adolescents.","volume":"32","author":"Jacobson","year":"2013","journal-title":"Pediatr Infect Dis J"},{"issue":"44","key":"poi200034r18","doi-asserted-by":"publisher","first-page":"5273","DOI":"10.1016\/j.vaccine.2016.09.003","article-title":"Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine.","volume":"34","author":"Robertson","year":"2016","journal-title":"Vaccine"},{"issue":"8","key":"poi200034r19","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.vaccine.2019.01.008","article-title":"Persistence of bactericidal antibodies 4 years after a booster dose of quadrivalent meningococcal diphtheria toxoid conjugate vaccine (MenACWY-D).","volume":"37","author":"Robertson","year":"2019","journal-title":"Vaccine"},{"issue":"5","key":"poi200034r20","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1586\/14760584.2016.1130628","article-title":"Routinely vaccinating adolescents against meningococcus: targeting transmission & disease.","volume":"15","author":"Vetter","year":"2016","journal-title":"Expert Rev Vaccines"},{"issue":"3","key":"poi200034r21","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/cid\/cis892","article-title":"Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity.","volume":"56","author":"Kristiansen","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"5","key":"poi200034r22","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1086\/527401","article-title":"Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity.","volume":"197","author":"Maiden","year":"2008","journal-title":"J Infect Dis"},{"key":"poi200034r23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/978-3-319-10018-0","article-title":"Effectiveness of immunoprophylaxis in suppressing carriage of Neisseria meningitidis in the military environment.","volume":"836","author":"Korzeniewski","year":"2015","journal-title":"Adv Exp Med Biol"},{"issue":"4","key":"poi200034r24","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1093\/infdis\/jix596","article-title":"Limited impact of adolescent meningococcal ACWY vaccination on Neisseria meningitidis serogroup W carriage in university students.","volume":"217","author":"Oldfield","year":"2018","journal-title":"J Infect Dis"},{"issue":"9960","key":"poi200034r25","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1016\/S0140-6736(14)60842-4","article-title":"Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial.","volume":"384","author":"Read","year":"2014","journal-title":"Lancet"},{"issue":"10","key":"poi200034r26","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1097\/00006454-199710000-00015","article-title":"Tobacco smoke as a risk factor for meningococcal disease.","volume":"16","author":"Fischer","year":"1997","journal-title":"Pediatr Infect Dis J"},{"issue":"14","key":"poi200034r27","doi-asserted-by":"publisher","first-page":"361","DOI":"10.15585\/mmwr.mm6514a1","article-title":"Tobacco use among middle and high school students\u2014United States, 2011-2015.","volume":"65","author":"Singh","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"24","key":"poi200034r28","doi-asserted-by":"publisher","first-page":"623","DOI":"10.15585\/mmwr.mm6524a4","article-title":"State and local comprehensive smoke-free laws for worksites, restaurants, and bars\u2014United States, 2015.","volume":"65","author":"Tynan","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"44","key":"poi200034r29","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.15585\/mmwr.mm6744a2","article-title":"Tobacco product use among adults\u2014United States, 2017.","volume":"67","author":"Wang","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"poi200034r31","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1093\/jac\/dkt301","article-title":"Antibiotic prescribing for adults in ambulatory care in the USA, 2007-09.","volume":"69","author":"Shapiro","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"poi200034r30","author":"MacLennan"},{"key":"poi200034r7","unstructured":"Centers for Disease Control and Prevention. National Notifiable Diseases Surveillance System (NNDSS). Updated March 13, 2019. Accessed June 5, 2017. https:\/\/wwwn.cdc.gov\/nndss\/"},{"key":"poi200034r8","unstructured":"Centers for Disease Control and Prevention. Active Bacterial Core surveillance (ABCs). Updated July 17, 2018. Accessed June 5, 2017. https:\/\/www.cdc.gov\/abcs\/index.html"},{"key":"poi200034r9","unstructured":"Centers for Disease Control and Prevention. Meningococcal disease: surveillance. Updated May 31, 2019. Accessed June 14, 2020. https:\/\/www.cdc.gov\/meningococcal\/surveillance\/index.html"},{"key":"poi200034r11","unstructured":"Centers for Disease Control and Prevention. National population projections 2014-2060 request. Accessed November 14, 2018. https:\/\/wonder.cdc.gov\/population-projections-2014-2060.html?"},{"key":"poi200034r32","unstructured":"Centers for Disease Control and Prevention. Meningococcal disease surveillance. Updated May 31, 2019. Accessed November 18, 2018. https:\/\/www.cdc.gov\/meningococcal\/surveillance\/index.html#enhanced-reports2019"}],"container-title":["JAMA Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapediatrics\/articlepdf\/2768552\/jamapediatrics_mbaeyi_2020_oi_200034_1598544876.51739.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T15:06:16Z","timestamp":1599577576000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapediatrics\/fullarticle\/2768552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,1]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapediatrics.2020.1990","relation":{},"ISSN":["2168-6203"],"issn-type":[{"value":"2168-6203","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,1]]}}}